BRIEF-Vistra To Acquire Natural Gas Assets, Building On Industry-Leading Generation Portfolio To Better Serve Customers-March 2024-www.financetom.com

BRIEF-Vistra To Acquire Natural Gas Assets, Building On Industry-Leading Generation Portfolio To Better Serve Customers

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Vistra To Acquire Natural Gas Assets, Building On Industry-Leading Generation Portfolio To Better Serve Customers

May 26, 2025 9:09 AM

May 15 (Reuters) - Vistra Corp ( VST ):

* VISTRA TO ACQUIRE NATURAL GAS ASSETS, BUILDING ON

INDUSTRY-LEADING GENERATION PORTFOLIO TO BETTER SERVE CUSTOMERS

* VISTRA CORP ( VST ) - ACQUISITION VALUED AT $1.9 BILLION OR $743

PER KW

* VISTRA CORP ( VST ) - DEAL FUNDED BY TERM LOAN AND CASH ON HAND

Source text:

Further company coverage:

Previous page： Sun Life Announces Leadership Changes for Sun Life Canada Next page： BriaCell Reports Positive Data for Bria-IMT in Phase 2 Metastatic Breast Cancer Study - Shares Soar Premarket

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Sun Life Announces Leadership Changes for Sun Life Canada

Sep 11, 2024

08:21 AM EDT, 09/11/2024 (MT Newswires) -- Sun Life (SLF.TO, SLF) on Wednesday said Jacques Goulet has been named executive chair of Sun Life Canada while Jessica Tan succeeds him as president of Sun Life Canada. The two will assume their new positions on September 30. Goulet, who joined Sun Life in 2018, will also continue as the chair of...

BriaCell Reports Positive Data for Bria-IMT in Phase 2 Metastatic Breast Cancer Study - Shares Soar Premarket

Sep 11, 2024

08:19 AM EDT, 09/11/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Wednesday it yielded positive overall survival data in a phase 2 late-stage metastatic breast cancer study evaluating Bria-IMT in combination with an immune check point inhibitor. The 54-patient study showed median survival of 15.6 months in patients treated with Bria-MT compared with 6.7 to 9.3 months for...

Eupraxia Pharmaceuticals Reports Positive Data from RESOLVE Trial

Sep 11, 2024

08:15 AM EDT, 09/11/2024 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) on Wednesday announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (EoE), an allergic condition that causes the esophagus to be inflamed and not contract properly. The results from the fourth...

Poet Technologies Combines Optical Engine With InSiGa's EML Driver

Sep 11, 2024

08:15 AM EDT, 09/11/2024 (MT Newswires) -- Poet Technologies ( POET ) and Chengdu InSiGa Semiconductor Technologies said Wednesday they have developed a solution for 200Gx4 applications using Poet's 200Gx4 transmit optical engine and InSiGa's 200G/lane EML driver ISG-D9616 for 800G and 1.6T modules. The companies will showcase the new product at the China International Optoelectronic Expo until Friday, Poet...